Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
28 hedge funds and large institutions have $12.6M invested in Vyant Bio, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 9 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
22% more capital invested
Capital invested by funds: $10.4M → $12.6M (+$2.25M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 32 → 28 (-4)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$799K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$770K |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$733K |
| 4 |
Renaissance Technologies
New York
|
+$468K |
| 5 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
+$426K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$139K |
| 2 |
Two Sigma Investments
New York
|
-$116K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
-$104K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$102K |
| 5 |
Millennium Management
New York
|
-$69K |
VYNT Hedge Fund Activity: Q2 2017 in Review
28 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q2 2017, worth a combined $12.6M — up 22% from $10.4M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of VYNT and 5 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 10 added.
The largest buyer was UBS Group, adding an estimated $799K. The largest seller was Panagora Asset Management, cutting an estimated $139K.
- 28 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q2 2017, down from 32 in Q1 2017.
- Funds reported $12.6M of Vyant Bio, Inc. Common Stock stock for Q2 2017, up 22% quarter-over-quarter.
- 5 funds opened new Vyant Bio, Inc. Common Stock positions in Q2 2017 and 9 closed out, a net change of -4 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q2 2017 was UBS Group, an estimated $799K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q2 2017 was Panagora Asset Management, an estimated $139K sold.
Based on aggregated 13F filings for Q2 2017.